NeurologyLive®
@neurologylive.bsky.social
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments
Read our coverage: neurologylive.com
Read our coverage: neurologylive.com
New #NeuroVoices interview 🚨
Dr. Christina Briscoe highlights why rapid #diagnosis and early #treatment are critical for infantile epileptic spasms—and why care still varies widely. More work is needed on pathways, access, and equity
Read More: www.neurologylive.com/view/neurovo...
#Epilepsy
Dr. Christina Briscoe highlights why rapid #diagnosis and early #treatment are critical for infantile epileptic spasms—and why care still varies widely. More work is needed on pathways, access, and equity
Read More: www.neurologylive.com/view/neurovo...
#Epilepsy
NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision...
www.neurologylive.com
November 26, 2025 at 2:07 PM
New #NeuroVoices interview 🚨
Dr. Christina Briscoe highlights why rapid #diagnosis and early #treatment are critical for infantile epileptic spasms—and why care still varies widely. More work is needed on pathways, access, and equity
Read More: www.neurologylive.com/view/neurovo...
#Epilepsy
Dr. Christina Briscoe highlights why rapid #diagnosis and early #treatment are critical for infantile epileptic spasms—and why care still varies widely. More work is needed on pathways, access, and equity
Read More: www.neurologylive.com/view/neurovo...
#Epilepsy
📣 New FDA Approval
The #FDA has approved the intrathecal form of #SMA gene therapy Itvisma for patients 2+. STEER showed meaningful motor gains and #STRENGTH confirmed safety in those switching from Spinraza/Evrysdi. 💙🧬
Read more here: www.neurologylive.com/view/fda-app...
#Approval #Neurology
The #FDA has approved the intrathecal form of #SMA gene therapy Itvisma for patients 2+. STEER showed meaningful motor gains and #STRENGTH confirmed safety in those switching from Spinraza/Evrysdi. 💙🧬
Read more here: www.neurologylive.com/view/fda-app...
#Approval #Neurology
FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.
www.neurologylive.com
November 25, 2025 at 2:11 PM
📣 New FDA Approval
The #FDA has approved the intrathecal form of #SMA gene therapy Itvisma for patients 2+. STEER showed meaningful motor gains and #STRENGTH confirmed safety in those switching from Spinraza/Evrysdi. 💙🧬
Read more here: www.neurologylive.com/view/fda-app...
#Approval #Neurology
The #FDA has approved the intrathecal form of #SMA gene therapy Itvisma for patients 2+. STEER showed meaningful motor gains and #STRENGTH confirmed safety in those switching from Spinraza/Evrysdi. 💙🧬
Read more here: www.neurologylive.com/view/fda-app...
#Approval #Neurology
🧠 This Week on NeurologyLive®
From cutting-edge clinical insights to expert-led analyses, #NeurologyLive is diving into the hottest topics in #neurology this week.
Explore what’s coming and stay ahead in the field of #neurological care: www.neurologylive.com/view/this-we...
#NeuroTwitter #Preview
From cutting-edge clinical insights to expert-led analyses, #NeurologyLive is diving into the hottest topics in #neurology this week.
Explore what’s coming and stay ahead in the field of #neurological care: www.neurologylive.com/view/this-we...
#NeuroTwitter #Preview
This Week on NeurologyLive® — November 24, 2025 | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Here's some of what is coming soon to NeurologyLive® this week.
www.neurologylive.com
November 24, 2025 at 2:16 PM
🧠 This Week on NeurologyLive®
From cutting-edge clinical insights to expert-led analyses, #NeurologyLive is diving into the hottest topics in #neurology this week.
Explore what’s coming and stay ahead in the field of #neurological care: www.neurologylive.com/view/this-we...
#NeuroTwitter #Preview
From cutting-edge clinical insights to expert-led analyses, #NeurologyLive is diving into the hottest topics in #neurology this week.
Explore what’s coming and stay ahead in the field of #neurological care: www.neurologylive.com/view/this-we...
#NeuroTwitter #Preview
🧠 New insights in #CIDP care:
Dr. Amit Sachdev highlights how personalized treatment—IVIg, SCIG, and emerging targeted therapies—can help patients move beyond the “maintenance plateau.”
More flexibility, better long-term outcomes ✨
Read More: www.neurologylive.com/view/optimiz...
#Neurology
Dr. Amit Sachdev highlights how personalized treatment—IVIg, SCIG, and emerging targeted therapies—can help patients move beyond the “maintenance plateau.”
More flexibility, better long-term outcomes ✨
Read More: www.neurologylive.com/view/optimiz...
#Neurology
Optimizing Treatment Selection and Moving Beyond the Plateau | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Panelist discuss individualized treatment strategies that balance efficacy, tolerability, and lifestyle considerations to move patients beyond maintenance plateaus in chronic inflammatory demyelinatin...
www.neurologylive.com
November 21, 2025 at 3:01 PM
🧠 New insights in #CIDP care:
Dr. Amit Sachdev highlights how personalized treatment—IVIg, SCIG, and emerging targeted therapies—can help patients move beyond the “maintenance plateau.”
More flexibility, better long-term outcomes ✨
Read More: www.neurologylive.com/view/optimiz...
#Neurology
Dr. Amit Sachdev highlights how personalized treatment—IVIg, SCIG, and emerging targeted therapies—can help patients move beyond the “maintenance plateau.”
More flexibility, better long-term outcomes ✨
Read More: www.neurologylive.com/view/optimiz...
#Neurology
“Every stroke is different… and so is every recovery.”
At #AAPMR2025, Dr. Talya Fleming talked about why access to stroke rehab still isn’t equal—and how new tech and home-based care could help.
Great Insights on what it takes to rebuild life after #stroke:
www.neurologylive.com/view/underst...
At #AAPMR2025, Dr. Talya Fleming talked about why access to stroke rehab still isn’t equal—and how new tech and home-based care could help.
Great Insights on what it takes to rebuild life after #stroke:
www.neurologylive.com/view/underst...
Understanding Access to Rehabilitation for Stroke Survivors: Talya Fleming, MD | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The medical director of the stroke recovery program at JFK Johnson Rehabilitation Institute at Hackensack Meridian Health provided clinical insights into her presentation focused on expanding rehab ca...
www.neurologylive.com
November 20, 2025 at 2:20 PM
“Every stroke is different… and so is every recovery.”
At #AAPMR2025, Dr. Talya Fleming talked about why access to stroke rehab still isn’t equal—and how new tech and home-based care could help.
Great Insights on what it takes to rebuild life after #stroke:
www.neurologylive.com/view/underst...
At #AAPMR2025, Dr. Talya Fleming talked about why access to stroke rehab still isn’t equal—and how new tech and home-based care could help.
Great Insights on what it takes to rebuild life after #stroke:
www.neurologylive.com/view/underst...
🚨 New hope in Parkinson research!
At #MDS2025, Dr. Tanya Simuni highlighted major breakthroughs in disease-modifying therapy trials for Parkinson disease. 🧠✨
Read more: www.neurologylive.com/view/neurovo...
#Parkinson #Neurology #ClinicalTrials #NeuroScience #PD
At #MDS2025, Dr. Tanya Simuni highlighted major breakthroughs in disease-modifying therapy trials for Parkinson disease. 🧠✨
Read more: www.neurologylive.com/view/neurovo...
#Parkinson #Neurology #ClinicalTrials #NeuroScience #PD
NeuroVoices: Tanya Simuni, MD, FAAN, on Emerging Directions in Disease-Modifying Therapy Trials for Parkinson Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
At MDS 2025, the professor of neurology at Northwestern University Feinberg School of Medicine discussed the evolving landscape of disease-modifying clinical trials in Parkinson disease.
www.neurologylive.com
November 19, 2025 at 2:21 PM
🚨 New hope in Parkinson research!
At #MDS2025, Dr. Tanya Simuni highlighted major breakthroughs in disease-modifying therapy trials for Parkinson disease. 🧠✨
Read more: www.neurologylive.com/view/neurovo...
#Parkinson #Neurology #ClinicalTrials #NeuroScience #PD
At #MDS2025, Dr. Tanya Simuni highlighted major breakthroughs in disease-modifying therapy trials for Parkinson disease. 🧠✨
Read more: www.neurologylive.com/view/neurovo...
#Parkinson #Neurology #ClinicalTrials #NeuroScience #PD
New study in Headache shows Nerivio® REN wearable delivers 3 years of stable migraine relief with no tachyphylaxis
🎉 Drug-free, app-controlled, and effective for both youth & adults.
⏱️ Early use = up to 2× better outcomes!
👉 Read more & join the discussion: www.neurologylive.com/view/nerivio...
🎉 Drug-free, app-controlled, and effective for both youth & adults.
⏱️ Early use = up to 2× better outcomes!
👉 Read more & join the discussion: www.neurologylive.com/view/nerivio...
Nerivio® REN Wearable Delivers Consistent Drug-Free Relief Over Three Years, Study Shows | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
A new study confirms the Nerivio REN wearable provides long-term, drug-free migraine relief without dosage increases, ensuring consistent effectiveness over three years.
www.neurologylive.com
November 18, 2025 at 2:43 PM
New study in Headache shows Nerivio® REN wearable delivers 3 years of stable migraine relief with no tachyphylaxis
🎉 Drug-free, app-controlled, and effective for both youth & adults.
⏱️ Early use = up to 2× better outcomes!
👉 Read more & join the discussion: www.neurologylive.com/view/nerivio...
🎉 Drug-free, app-controlled, and effective for both youth & adults.
⏱️ Early use = up to 2× better outcomes!
👉 Read more & join the discussion: www.neurologylive.com/view/nerivio...
🧠 New week, new insights on NeurologyLive®!
We’re covering the biggest conversations in #neurology —clinical updates, expert perspectives, and more.
Don't miss out! Take a look & dive into the full lineup here: www.neurologylive.com/view/this-we...
#BrainHealth #Updates #Interviews #News #Coverage
We’re covering the biggest conversations in #neurology —clinical updates, expert perspectives, and more.
Don't miss out! Take a look & dive into the full lineup here: www.neurologylive.com/view/this-we...
#BrainHealth #Updates #Interviews #News #Coverage
This Week on NeurologyLive® — November 17, 2025 | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Here's some of what is coming soon to NeurologyLive® this week.
www.neurologylive.com
November 17, 2025 at 2:10 PM
🧠 New week, new insights on NeurologyLive®!
We’re covering the biggest conversations in #neurology —clinical updates, expert perspectives, and more.
Don't miss out! Take a look & dive into the full lineup here: www.neurologylive.com/view/this-we...
#BrainHealth #Updates #Interviews #News #Coverage
We’re covering the biggest conversations in #neurology —clinical updates, expert perspectives, and more.
Don't miss out! Take a look & dive into the full lineup here: www.neurologylive.com/view/this-we...
#BrainHealth #Updates #Interviews #News #Coverage
🚨 New Podcast Ep.!
NEALS 2025: Takeaways That Matter for ALS Care - Featuring Dr. Berry and Dr. Andrews!
Listen as they reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for #ALS.
👂 ➡️ www.neurologylive.com/view/episode...
#MindMoments #Podcast
NEALS 2025: Takeaways That Matter for ALS Care - Featuring Dr. Berry and Dr. Andrews!
Listen as they reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for #ALS.
👂 ➡️ www.neurologylive.com/view/episode...
#MindMoments #Podcast
Episode 154: NEALS 2025: Takeaways That Matter for ALS Care | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Berry, MD, MPH; and Jinsy Andrews, MD, MSc. [LISTEN TIME: 28 minutes]
www.neurologylive.com
November 14, 2025 at 2:08 PM
🚨 New Podcast Ep.!
NEALS 2025: Takeaways That Matter for ALS Care - Featuring Dr. Berry and Dr. Andrews!
Listen as they reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for #ALS.
👂 ➡️ www.neurologylive.com/view/episode...
#MindMoments #Podcast
NEALS 2025: Takeaways That Matter for ALS Care - Featuring Dr. Berry and Dr. Andrews!
Listen as they reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for #ALS.
👂 ➡️ www.neurologylive.com/view/episode...
#MindMoments #Podcast
Breakthrough for #Parkinson patients:
iPSC therapy UX-DA001 boosts motor function & dopamine activity—without serious side effects. Learn how #CellTherapy may transform brain repair. 🧠
Read the full story 👉 www.neurologylive.com/view/therape... #StemCellTherapy #NeuroResearch #Neurology #Health
iPSC therapy UX-DA001 boosts motor function & dopamine activity—without serious side effects. Learn how #CellTherapy may transform brain repair. 🧠
Read the full story 👉 www.neurologylive.com/view/therape... #StemCellTherapy #NeuroResearch #Neurology #Health
Therapeutic Potential and Early Promise Behind Stem Cell Therapy UX-DA001 in Parkinson Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Liche Zhou, MD, of the department of neurology at Jiang University School of Medicine, provided commentary on new phase 1 data on an iPSC-targeted cell therapy presented at the 2025 MDS Congress.
www.neurologylive.com
November 13, 2025 at 2:07 PM
Breakthrough for #Parkinson patients:
iPSC therapy UX-DA001 boosts motor function & dopamine activity—without serious side effects. Learn how #CellTherapy may transform brain repair. 🧠
Read the full story 👉 www.neurologylive.com/view/therape... #StemCellTherapy #NeuroResearch #Neurology #Health
iPSC therapy UX-DA001 boosts motor function & dopamine activity—without serious side effects. Learn how #CellTherapy may transform brain repair. 🧠
Read the full story 👉 www.neurologylive.com/view/therape... #StemCellTherapy #NeuroResearch #Neurology #Health
🌍 A new dawn for #RareDisease care: #FDA approves Kygevvi, the first treatment for thymidine kinase 2 deficiency (TK2d).
💡 Data show an 86% reduction in mortality risk — a life-changing advance for patients & families.
Read here: www.neurologylive.com/view/neurovo...
#Neurology #Innovation
💡 Data show an 86% reduction in mortality risk — a life-changing advance for patients & families.
Read here: www.neurologylive.com/view/neurovo...
#Neurology #Innovation
NeuroVoices: Fabian Somers, PhD, on the First Approved Drug for Thymidine Kinase 2 Deficiency | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The vice president and Asset Head of Rare and Ultra-Rare Diseases at UCB provided clinical perspectives on the FDA approval of Kygevvi, the first marketed treatment specific for patients with thymidin...
www.neurologylive.com
November 12, 2025 at 3:58 PM
🌍 A new dawn for #RareDisease care: #FDA approves Kygevvi, the first treatment for thymidine kinase 2 deficiency (TK2d).
💡 Data show an 86% reduction in mortality risk — a life-changing advance for patients & families.
Read here: www.neurologylive.com/view/neurovo...
#Neurology #Innovation
💡 Data show an 86% reduction in mortality risk — a life-changing advance for patients & families.
Read here: www.neurologylive.com/view/neurovo...
#Neurology #Innovation
Caregivers are open to talking about social determinants of health (SDoH) — but prefer surveys over face-to-face discussions.
A new study finds many want to focus clinic time on their child’s care while still sharing key life factors that affect health.
🔗 ➡️ www.neurologylive.com/view/study-s...
A new study finds many want to focus clinic time on their child’s care while still sharing key life factors that affect health.
🔗 ➡️ www.neurologylive.com/view/study-s...
Study Shows Caregivers Willing to Discuss Social Determinants of Health in Pediatric Multidisciplinary Clinics | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Caregivers share insights on discussing social determinants of health in pediatric clinics, revealing preferences for surveys over in-person conversations.
www.neurologylive.com
November 11, 2025 at 2:08 PM
Caregivers are open to talking about social determinants of health (SDoH) — but prefer surveys over face-to-face discussions.
A new study finds many want to focus clinic time on their child’s care while still sharing key life factors that affect health.
🔗 ➡️ www.neurologylive.com/view/study-s...
A new study finds many want to focus clinic time on their child’s care while still sharing key life factors that affect health.
🔗 ➡️ www.neurologylive.com/view/study-s...
🧠 This Week on #NeurologyLive
From conference coverage to video interviews to up to the minute news — we’re diving into the latest research, expert insights, and clinical updates shaping the field of #neurology.
Don’t miss this week’s coverage 👉 www.neurologylive.com
#BrainHealth #NeurologyUpdates
From conference coverage to video interviews to up to the minute news — we’re diving into the latest research, expert insights, and clinical updates shaping the field of #neurology.
Don’t miss this week’s coverage 👉 www.neurologylive.com
#BrainHealth #NeurologyUpdates
November 10, 2025 at 2:25 PM
🧠 This Week on #NeurologyLive
From conference coverage to video interviews to up to the minute news — we’re diving into the latest research, expert insights, and clinical updates shaping the field of #neurology.
Don’t miss this week’s coverage 👉 www.neurologylive.com
#BrainHealth #NeurologyUpdates
From conference coverage to video interviews to up to the minute news — we’re diving into the latest research, expert insights, and clinical updates shaping the field of #neurology.
Don’t miss this week’s coverage 👉 www.neurologylive.com
#BrainHealth #NeurologyUpdates
⚡ EVs may reduce emissions — but could they raise neurologic risks globally?
Dr. Brad Racette (Barrow Neurological Institute) explores how EV production shifts environmental & neurotoxic burdens to the global south.
Read more 👉 www.neurologylive.com/view/overvie...
#EVs #Risks #Neurology #Health
Dr. Brad Racette (Barrow Neurological Institute) explores how EV production shifts environmental & neurotoxic burdens to the global south.
Read more 👉 www.neurologylive.com/view/overvie...
#EVs #Risks #Neurology #Health
Overviewing the Neurologic Risks Behind Electric Vehicles | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Brad Racette, MD, FAAN, the Kemper and Ethel Marley Chair for Neurology at Barrow Neurological Institute, discussed his keynote lecture on the neurologic health effects of electric vehicles and the gl...
www.neurologylive.com
November 7, 2025 at 3:27 PM
⚡ EVs may reduce emissions — but could they raise neurologic risks globally?
Dr. Brad Racette (Barrow Neurological Institute) explores how EV production shifts environmental & neurotoxic burdens to the global south.
Read more 👉 www.neurologylive.com/view/overvie...
#EVs #Risks #Neurology #Health
Dr. Brad Racette (Barrow Neurological Institute) explores how EV production shifts environmental & neurotoxic burdens to the global south.
Read more 👉 www.neurologylive.com/view/overvie...
#EVs #Risks #Neurology #Health
💡 Promising results for #ALS patients!
Phase 2a data show SPG302 (Spinogenix’s synaptic regenerative drug) slowed ALS progression by 76% vs historical controls, with 82% of patients showing stable or improved function.
Read more: www.neurologylive.com/view/prelimi...
#Neuroscience #Neurology
Phase 2a data show SPG302 (Spinogenix’s synaptic regenerative drug) slowed ALS progression by 76% vs historical controls, with 82% of patients showing stable or improved function.
Read more: www.neurologylive.com/view/prelimi...
#Neuroscience #Neurology
Preliminary Phase 2 Data Support Therapeutic Development of Synaptic Regenerative Drug SPG302 in ALS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Spinogenics presents promising data on SPG302, a daily tablet showing cognitive improvements in Alzheimer's patients with excellent safety profiles.
www.neurologylive.com
November 6, 2025 at 2:06 PM
💡 Promising results for #ALS patients!
Phase 2a data show SPG302 (Spinogenix’s synaptic regenerative drug) slowed ALS progression by 76% vs historical controls, with 82% of patients showing stable or improved function.
Read more: www.neurologylive.com/view/prelimi...
#Neuroscience #Neurology
Phase 2a data show SPG302 (Spinogenix’s synaptic regenerative drug) slowed ALS progression by 76% vs historical controls, with 82% of patients showing stable or improved function.
Read more: www.neurologylive.com/view/prelimi...
#Neuroscience #Neurology
In case you missed it:
🚨 Breaking: FDA Approves First Treatment for TK2 Deficiency
The #FDA has approved Kygevvi — a fixed-dose combo of doxecitine + doxribtine — as the first-ever therapy for thymidine kinase 2 deficiency.
Stay up to date here: www.neurologylive.com/view/fda-app...
#Neurology
🚨 Breaking: FDA Approves First Treatment for TK2 Deficiency
The #FDA has approved Kygevvi — a fixed-dose combo of doxecitine + doxribtine — as the first-ever therapy for thymidine kinase 2 deficiency.
Stay up to date here: www.neurologylive.com/view/fda-app...
#Neurology
FDA Approves Doxecitine and Doxribtimine Combination Therapy as First Treatment for Thymidine Kinase 2 Deficiency | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
UCB's Kygevvi becomes the first FDA-approved treatment for thymidine kinase 2 deficiency, offering hope to patients with this rare neuromuscular disorder.
www.neurologylive.com
November 5, 2025 at 4:15 PM
In case you missed it:
🚨 Breaking: FDA Approves First Treatment for TK2 Deficiency
The #FDA has approved Kygevvi — a fixed-dose combo of doxecitine + doxribtine — as the first-ever therapy for thymidine kinase 2 deficiency.
Stay up to date here: www.neurologylive.com/view/fda-app...
#Neurology
🚨 Breaking: FDA Approves First Treatment for TK2 Deficiency
The #FDA has approved Kygevvi — a fixed-dose combo of doxecitine + doxribtine — as the first-ever therapy for thymidine kinase 2 deficiency.
Stay up to date here: www.neurologylive.com/view/fda-app...
#Neurology
A new #Phase3 trial, RELIEVE, is underway to evaluate remibrutinib, a potent oral BTK inhibitor, in #gMG.
💊 Builds on strong safety data from autoimmune studies and FDA approval in CSU.
🧬 Could mark a new era in targeted gMG treatment.
Read here: www.neurologylive.com/view/new-pha...
#Neurology
💊 Builds on strong safety data from autoimmune studies and FDA approval in CSU.
🧬 Could mark a new era in targeted gMG treatment.
Read here: www.neurologylive.com/view/new-pha...
#Neurology
New Phase 3 Study to Evaluate Remibrutinib in Generalized Myasthenia Gravis Treatment | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
A phase 3 study evaluates remibrutinib's safety and efficacy for generalized myasthenia gravis, promising new treatment options for patients.
www.neurologylive.com
November 4, 2025 at 2:01 PM
A new #Phase3 trial, RELIEVE, is underway to evaluate remibrutinib, a potent oral BTK inhibitor, in #gMG.
💊 Builds on strong safety data from autoimmune studies and FDA approval in CSU.
🧬 Could mark a new era in targeted gMG treatment.
Read here: www.neurologylive.com/view/new-pha...
#Neurology
💊 Builds on strong safety data from autoimmune studies and FDA approval in CSU.
🧬 Could mark a new era in targeted gMG treatment.
Read here: www.neurologylive.com/view/new-pha...
#Neurology
🧠 This Week on NeurologyLive® — Nov 3, 2025
From #Alzheimer’s and #epilepsy to sleep and stroke, we’re diving into the week’s hottest topics in neurology. Explore expert insights, in-depth analyses, and clinical updates designed for professionals in the field.
🔗 neurologylive.com
#Neurology #Care
From #Alzheimer’s and #epilepsy to sleep and stroke, we’re diving into the week’s hottest topics in neurology. Explore expert insights, in-depth analyses, and clinical updates designed for professionals in the field.
🔗 neurologylive.com
#Neurology #Care
NeurologyLive - Clinical Neurology News and Neurology Expert Insights
NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.
neurologylive.com
November 3, 2025 at 2:05 PM
🧠 This Week on NeurologyLive® — Nov 3, 2025
From #Alzheimer’s and #epilepsy to sleep and stroke, we’re diving into the week’s hottest topics in neurology. Explore expert insights, in-depth analyses, and clinical updates designed for professionals in the field.
🔗 neurologylive.com
#Neurology #Care
From #Alzheimer’s and #epilepsy to sleep and stroke, we’re diving into the week’s hottest topics in neurology. Explore expert insights, in-depth analyses, and clinical updates designed for professionals in the field.
🔗 neurologylive.com
#Neurology #Care
Reposted by NeurologyLive®
The results from our #AI in #MultipleSclerosis survey are in. Take a look over on @neurologylive.bsky.social.
www.neurologylive.com/view/ai-in-m...
www.neurologylive.com/view/ai-in-m...
AI in MS: IJMSC Survey Results | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
A video that shares the sentiments and opinions of the IJMSC community on the use of artificial intelligence in multiple sclerosis care, research, and publication.
www.neurologylive.com
November 3, 2025 at 1:16 PM
The results from our #AI in #MultipleSclerosis survey are in. Take a look over on @neurologylive.bsky.social.
www.neurologylive.com/view/ai-in-m...
www.neurologylive.com/view/ai-in-m...
🎃 This Halloween, neurology meets history 📜
Avi Singh Gandh, MD, explores how the “bewitchments” of the 1692 Salem Witch Trials may reflect epilepsy, FND, and more —reminding us how science turns fear into understanding.
Read more: www.neurologylive.com/view/revisit...
#Halloween #AAN25 #Spooky
Avi Singh Gandh, MD, explores how the “bewitchments” of the 1692 Salem Witch Trials may reflect epilepsy, FND, and more —reminding us how science turns fear into understanding.
Read more: www.neurologylive.com/view/revisit...
#Halloween #AAN25 #Spooky
Revisiting the Salem Witch Trials Through a Modern Neurological Lens | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Avi Singh Gandh, MD, neurology resident at Emory University School of Medicine, reflected on how modern neurology can interpret the Salem Witch Trials.
www.neurologylive.com
October 31, 2025 at 1:08 PM
🎃 This Halloween, neurology meets history 📜
Avi Singh Gandh, MD, explores how the “bewitchments” of the 1692 Salem Witch Trials may reflect epilepsy, FND, and more —reminding us how science turns fear into understanding.
Read more: www.neurologylive.com/view/revisit...
#Halloween #AAN25 #Spooky
Avi Singh Gandh, MD, explores how the “bewitchments” of the 1692 Salem Witch Trials may reflect epilepsy, FND, and more —reminding us how science turns fear into understanding.
Read more: www.neurologylive.com/view/revisit...
#Halloween #AAN25 #Spooky
This #WorldStrokeDay, Cleveland Clinic’s Dr. Andrew Russman highlights how most strokes stem from identifiable and modifiable risks — and how precision medicine and heart–brain collaboration are reshaping prevention.
Read more via NeurologyLive®: www.neurologylive.com/view/honorin...
Read more via NeurologyLive®: www.neurologylive.com/view/honorin...
Honoring World Stroke Day: Insights on Systemic Stroke Risk and Prevention Strategies | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Andrew Russman, DO, medical director of Cleveland Clinic’s Comprehensive Stroke Center, shared insights on stroke awareness, prevention, and the growing importance of heart-brain collaboration in care...
www.neurologylive.com
October 30, 2025 at 1:04 PM
This #WorldStrokeDay, Cleveland Clinic’s Dr. Andrew Russman highlights how most strokes stem from identifiable and modifiable risks — and how precision medicine and heart–brain collaboration are reshaping prevention.
Read more via NeurologyLive®: www.neurologylive.com/view/honorin...
Read more via NeurologyLive®: www.neurologylive.com/view/honorin...
❤️ “Maintaining healthy numbers for Life’s Essential 8 can reduce the risk of #stroke and #dementia.”
— Dr. Mitch Elkind
Ahead of #WorldStrokeDay, NeurologyLive® spoke with Dr. Elkind on prevention, equity, and the future of brain health.
Read more: www.neurologylive.com/view/neurovo...
#Health
— Dr. Mitch Elkind
Ahead of #WorldStrokeDay, NeurologyLive® spoke with Dr. Elkind on prevention, equity, and the future of brain health.
Read more: www.neurologylive.com/view/neurovo...
#Health
NeuroVoices: Mitch Elkind, MD, MS, FAHA, on Enhancing Brain Health Amid World Stroke Day | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The chief science officer at the American Heart Association discusses the AHA’s priorities for stroke prevention, cross-specialty collaboration, and equitable care as clinicians mark World Stroke Day ...
www.neurologylive.com
October 29, 2025 at 1:19 PM
❤️ “Maintaining healthy numbers for Life’s Essential 8 can reduce the risk of #stroke and #dementia.”
— Dr. Mitch Elkind
Ahead of #WorldStrokeDay, NeurologyLive® spoke with Dr. Elkind on prevention, equity, and the future of brain health.
Read more: www.neurologylive.com/view/neurovo...
#Health
— Dr. Mitch Elkind
Ahead of #WorldStrokeDay, NeurologyLive® spoke with Dr. Elkind on prevention, equity, and the future of brain health.
Read more: www.neurologylive.com/view/neurovo...
#Health
🚨 FDA Accepts NDA for MK-6240 — a PET imaging agent targeting tau protein in #Alzheimer disease.
🔬 Developed by Lantheus, MK-6240 aims to improve early diagnosis and guide treatment strategies for patients with cognitive impairment.
📖 Read more: www.neurologylive.com/view/fda-acc...
#FDA #News
🔬 Developed by Lantheus, MK-6240 aims to improve early diagnosis and guide treatment strategies for patients with cognitive impairment.
📖 Read more: www.neurologylive.com/view/fda-acc...
#FDA #News
FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
The FDA accepts Lantheus' MK-6240 application, a promising PET imaging agent for Alzheimer disease, enhancing diagnosis and treatment strategies.
www.neurologylive.com
October 28, 2025 at 5:45 PM
🚨 FDA Accepts NDA for MK-6240 — a PET imaging agent targeting tau protein in #Alzheimer disease.
🔬 Developed by Lantheus, MK-6240 aims to improve early diagnosis and guide treatment strategies for patients with cognitive impairment.
📖 Read more: www.neurologylive.com/view/fda-acc...
#FDA #News
🔬 Developed by Lantheus, MK-6240 aims to improve early diagnosis and guide treatment strategies for patients with cognitive impairment.
📖 Read more: www.neurologylive.com/view/fda-acc...
#FDA #News
This Week’s Preview 🫣
Stay ahead in neurology with our latest coverage! Coming up: exclusive clinician interviews, continued conference insights, a new podcast episode, and more.
🕐 Take 5 minutes to stay informed → www.neurologylive.com/view/this-we...
#Neurology #Research
Stay ahead in neurology with our latest coverage! Coming up: exclusive clinician interviews, continued conference insights, a new podcast episode, and more.
🕐 Take 5 minutes to stay informed → www.neurologylive.com/view/this-we...
#Neurology #Research
This Week on NeurologyLive® — October 27, 2025 | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Here's some of what is coming soon to NeurologyLive® this week.
www.neurologylive.com
October 27, 2025 at 1:25 PM
This Week’s Preview 🫣
Stay ahead in neurology with our latest coverage! Coming up: exclusive clinician interviews, continued conference insights, a new podcast episode, and more.
🕐 Take 5 minutes to stay informed → www.neurologylive.com/view/this-we...
#Neurology #Research
Stay ahead in neurology with our latest coverage! Coming up: exclusive clinician interviews, continued conference insights, a new podcast episode, and more.
🕐 Take 5 minutes to stay informed → www.neurologylive.com/view/this-we...
#Neurology #Research
"Lifestyle factors are not secondary—they’re central"
New insights from Dr. James N. Brenton at the 2025 Child Neurology Society Annual Meeting on how #diet, vitamin D, and obesity impact pediatric MS progression—and why coordinated care matters.
Full article: www.neurologylive.com/view/integra...
New insights from Dr. James N. Brenton at the 2025 Child Neurology Society Annual Meeting on how #diet, vitamin D, and obesity impact pediatric MS progression—and why coordinated care matters.
Full article: www.neurologylive.com/view/integra...
Integrating Nutrition and Lifestyle Strategies in Pediatric Multiple Sclerosis Management | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
James N. Brenton, MD, director of the Pediatric MS and Related Disorders Clinic at the University of Virginia, discussed how lifestyle modification and multidisciplinary care can support disease manag...
www.neurologylive.com
October 24, 2025 at 1:13 PM
"Lifestyle factors are not secondary—they’re central"
New insights from Dr. James N. Brenton at the 2025 Child Neurology Society Annual Meeting on how #diet, vitamin D, and obesity impact pediatric MS progression—and why coordinated care matters.
Full article: www.neurologylive.com/view/integra...
New insights from Dr. James N. Brenton at the 2025 Child Neurology Society Annual Meeting on how #diet, vitamin D, and obesity impact pediatric MS progression—and why coordinated care matters.
Full article: www.neurologylive.com/view/integra...